Haskell v. Goldman, Sachs & Co. (In Re Genesis Health Ventures, Inc.)

324 B.R. 510, 2005 WL 1038920
CourtUnited States Bankruptcy Court, D. Delaware
DecidedMay 3, 2005
Docket17-12785
StatusPublished
Cited by6 cases

This text of 324 B.R. 510 (Haskell v. Goldman, Sachs & Co. (In Re Genesis Health Ventures, Inc.)) is published on Counsel Stack Legal Research, covering United States Bankruptcy Court, D. Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Haskell v. Goldman, Sachs & Co. (In Re Genesis Health Ventures, Inc.), 324 B.R. 510, 2005 WL 1038920 (Del. 2005).

Opinion

AMENDED OPINION ON JOINT MOTION TO DISMISS

JUDITH H. WIZMUR, Bankruptcy Judge.

The defendants jointly move to dismiss the plaintiffs’ complaint in its entirety because it is time-barred under section 1144, because it violates the order of confirmation, because it is barred by the doctrines of res judicata and/or collateral estoppel, and because it fails to assert a claim for fraud with specificity as required by Rule 9(b). I conclude that plaintiffs’ complaint as against the debtor is barred by operation of section 1144 and the order of confirmation, and must therefore be dismissed. Plaintiffs’ complaint as against the remaining defendants is barred by the doctrines of res judicata and collateral estoppel. The defendants’ motion is granted, and the complaint is dismissed in its entirety.

FACTS

The Genesis Health Ventures, Inc. (“Genesis”) and Multicare AMC, Inc. (“Multicare”) debtors filed separate Chapter 11 bankruptcy cases on June 22, 2000. The debtors’ Joint Plan of Reorganization was filed on July 6, 2001 and confirmation hearings were held on August 28 and 29, 2001. Debtors’ plan was confirmed on September 12, 2001 by written opinion. See In re Genesis Health Ventures, Inc., 266 B.R. 591 (Bankr.D.Del.2001), appeal dismissed, 280 B.R. 389 (D.Del.2002).

Two and a half years later, plaintiffs filed this complaint on January 24, 2004 in the Supreme Court for the State of New York. The complaint was removed to the United States District Court for the Southern District of New York, transferred to the United States District Court for the District of Delaware, and then referred to the Delaware bankruptcy court.

The plaintiffs are comprised of 275 investors who, on October 2, 2001, collectively held 55% of all debentures (“Senior Subordinated Notes”) issued by Genesis, with a face value in excess of $205 million. The debentures were subordinated to about $1.3 billion in senior debt. Defendant Goldman Sachs & Co. purchased about half of the Genesis senior debt par-ticipations shortly before the debtors’ bankruptcy filings. Goldman became the largest senior creditor of both Genesis and Multicare, and served as the underwriter for the DIP and exit financing.

Plaintiffs allege that Goldman, Highland Capital Partners, another senior debt participant, and Mellon Bank N.A., the debtors’ lead senior lender bank, (“Senior Lenders”) “conspired with Genesis management to put the Company into bankruptcy and ‘cram down’ a reorganization plan that would eliminate junior creditors (including plaintiffs) and existing stockholders, while conveying virtually total ownership of Genesis to the senior creditors.” Complaint at 8. The confirmed plan merged Genesis and Multicare, extinguished the Old Common Stock of both companies, and distributed about 94% of the newly issued stock of the reorganized, combined entities to the Senior Lenders. The junior creditors, including the Genesis Senior Subordinated Note claimants, received an approximate dividend of 7.34%, plus New Warrants.

Plaintiffs allege that the enterprise value of Genesis was misrepresented at confirmation as being about $1.3 billion. The enterprise value was based on a multiple of the Genesis budgeted EBITDA (earnings before interest, taxes, depreciation, and amortization) for 2001, which was projected at $158 million, down from between $205 and $210 million for the fiscal years *514 1998 and 1999. In August 2001, shortly before the confirmation hearing, the debt- or presented its historical LTM EBITDA (last twelve months EBITDA) for the preceding 12 month period, which supported the $158 million projection. Plaintiffs contend that “both the Budgeted EBITDA projections and the LTM EBITDA were ‘cooked’, to depress EBITDA and thereby depress the valuation of Genesis.” Complaint at 11. Because the LTM EBITDA was presented only six days prior to the confirmation hearing, plaintiffs complain that they were unable to challenge the EBITDA in a timely manner.

Plaintiffs assert causes of action for fraud, conspiracy to commit fraud and gross negligence. More specifically, plaintiffs assert in Count One of their complaint that

Genesis and Hager [the Chief Financial Officer of Genesis] were directly involved in the preparation of all the misleading financial information that led to the under-valuation of Genesis.
Goldman, Mellon and Highland controlled this entire process, periodically reviewing in detail the financial information prepared by Genesis management on a monthly basis, to assure that EBITDA data were matching the ‘target’ of about $158 million, and that sufficient adjustments were being made to the budgeted EBITDA to bring about the same result. They offered enormous financial inducements to Genesis management to perpetrate this fraud, and they were the principal beneficiaries of the fraud. Goldman also took all the steps needed to freeze MC’s cash and lines of credit so that it could not pay its obligations to Genesis, thus forcing Genesis to draw down almost $200 million from its DIP lending facility.

Complaint at ¶¶ 184, 185. In support of these allegations, plaintiffs contend that Genesis management improperly decreased the debtors’ EBITDA by deducting a host of unsubstantiated and unwarranted items.

In Count Two, plaintiffs allege that Goldman, Mellon and Highland were aware that the financial information being released by Genesis, and upon which the reorganization valuation of the Company would be determined, was false and misleading and had been designed to defraud the junior creditors of Genesis, and would be relied upon by the plaintiffs and the Court.
Goldman, Mellon and Highland conspired with, orchestrated and rewarded Genesis and its management, and in particular defendant George Hager, for perpetrating this fraud.

Complaint at ¶¶ 191,192. In Count Three, plaintiffs allege that

By virtue of their positions as debtor in a bankruptcy proceeding, as the chief financial officer of the debtor, as senior creditors of the debtor, and as proponents of a bankruptcy reorganization plan that would drastically affect the junior creditors, defendants owed the junior creditors of Genesis a duty of care, including the duty to provide fair, accurate and complete information. Defendants violated that duty of care by disseminating false and misleading financial information that misled the bankruptcy court and the plaintiffs concerning the true financial condition and prospects of Genesis. Defendants’ conduct was such an extreme and severe departure from due care as to constitute gross negligence, and was therefore not released as a result of the Genesis bankruptcy.

Complaint at ¶¶ 195, 196. Plaintiffs believe that if Genesis had been properly valued, there would have been sufficient value for the subordinated debenture holders to recover the full par value of their *515 debentures. They seek an award of damages in an amount not less than $200 million, plus interest, costs and fees.

Defendants view plaintiffs’ complaint as another attempt to alter the distribution to creditors provided for under the debtors’ confirmed Chapter 11 plan.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

In re Apex Long Term Acute Care Katy, L.P.
599 B.R. 314 (S.D. Texas, 2019)
Johnson v. Stemple (In Re Stemple)
361 B.R. 778 (E.D. Virginia, 2007)
Haskell v. Goldman, Sachs & Co.
340 B.R. 729 (D. Delaware, 2006)
In Re Genesis Health Ventures, Inc.
340 B.R. 729 (D. Delaware, 2006)

Cite This Page — Counsel Stack

Bluebook (online)
324 B.R. 510, 2005 WL 1038920, Counsel Stack Legal Research, https://law.counselstack.com/opinion/haskell-v-goldman-sachs-co-in-re-genesis-health-ventures-inc-deb-2005.